CN112190707A - anti-HPV recombinant human gel and preparation method thereof - Google Patents
anti-HPV recombinant human gel and preparation method thereof Download PDFInfo
- Publication number
- CN112190707A CN112190707A CN202010977040.7A CN202010977040A CN112190707A CN 112190707 A CN112190707 A CN 112190707A CN 202010977040 A CN202010977040 A CN 202010977040A CN 112190707 A CN112190707 A CN 112190707A
- Authority
- CN
- China
- Prior art keywords
- stirring
- recombinant human
- hpv
- percent
- hpv recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 238000001879 gelation Methods 0.000 title description 2
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 35
- 239000000022 bacteriostatic agent Substances 0.000 claims abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000008213 purified water Substances 0.000 claims abstract description 25
- 108060003951 Immunoglobulin Proteins 0.000 claims abstract description 23
- 102000018358 immunoglobulin Human genes 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 22
- 239000000314 lubricant Substances 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 239000002562 thickening agent Substances 0.000 claims abstract description 15
- 238000003756 stirring Methods 0.000 claims description 108
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 12
- 229920002125 Sokalan® Polymers 0.000 claims description 12
- 229960001631 carbomer Drugs 0.000 claims description 12
- 238000011049 filling Methods 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 12
- 238000004659 sterilization and disinfection Methods 0.000 claims description 12
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 11
- 229920002498 Beta-glucan Polymers 0.000 claims description 11
- 102000008186 Collagen Human genes 0.000 claims description 11
- 108010035532 Collagen Proteins 0.000 claims description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 11
- 229920001436 collagen Polymers 0.000 claims description 11
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 10
- 229920001661 Chitosan Polymers 0.000 claims description 10
- 239000011259 mixed solution Substances 0.000 claims description 10
- 229960005323 phenoxyethanol Drugs 0.000 claims description 10
- -1 polyhexamethylene guanidine Polymers 0.000 claims description 10
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims description 10
- 102000002322 Egg Proteins Human genes 0.000 claims description 6
- 108010000912 Egg Proteins Proteins 0.000 claims description 6
- 235000013345 egg yolk Nutrition 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 20
- 231100000572 poisoning Toxicity 0.000 abstract description 3
- 230000000607 poisoning effect Effects 0.000 abstract description 3
- 239000000499 gel Substances 0.000 description 48
- 241000701806 Human papillomavirus Species 0.000 description 27
- 239000003814 drug Substances 0.000 description 14
- 206010008342 Cervix carcinoma Diseases 0.000 description 8
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 8
- 201000010881 cervical cancer Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000000829 suppository Substances 0.000 description 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- 206010059313 Anogenital warts Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 206010061424 Anal cancer Diseases 0.000 description 2
- 208000007860 Anus Neoplasms Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 201000011165 anus cancer Diseases 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 210000004995 male reproductive system Anatomy 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 206010046885 vaginal cancer Diseases 0.000 description 2
- 208000013139 vaginal neoplasm Diseases 0.000 description 2
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010018143 Genital candidiasis Diseases 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 206010034878 phimosis Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000011453 reproductive organ cancer Diseases 0.000 description 1
- 208000015608 reproductive system cancer Diseases 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides an anti-HPV recombinant human gel and a preparation method thereof, and relates to the technical field of biomedicine. The anti-HPV recombinant human gel comprises: the raw materials comprise the following components in percentage by weight: 1 to 20 percent of compound yolk immunoglobulin, 0.1 to 5 percent of bacteriostatic agent, 0.5 to 10 percent of lubricant, 0.1 to 10 percent of thickening agent and the balance of purified water. The anti-HPV recombinant human gel and the preparation method thereof provided by the invention have the advantages of small side effect, good curative effect and difficulty in causing poisoning.
Description
Technical Field
The invention relates to the technical field of biomedicine, in particular to an anti-HPV recombinant human gel and a preparation method thereof.
Background
With changes in life concepts and deterioration of the surrounding environment, genital tract infections are becoming more and more common and frequently occurring in women. The HPV is also called human papilloma virus, is an epitheliotropic virus and is widely distributed in human and animals, and the HPV mainly causes wart lesions of skin and mucous membrane. According to the relation between the HPV and tumorigenesis, the HPV can be divided into high-risk type and low-risk type, wherein the HPV infection of the high-risk type is proved to be the main reason for inducing genital cancer including female cervical cancer; the low risk type mainly causes condyloma acuminatum. According to the statistics of the world health organization, 52.9 ten thousand cervical cancer cases are generated each year around the world, about 25 ten thousand people die of the cervical cancer, and more than 90 percent of the cervical cancer cases come from developing countries. The mortality rate for cervical cancer is second highest in women 25-45 years of age. HPV can cause benign tumors and warts in humans, and both men and women can be infected with HPV. The types of diseases that HPV virus may cause are anal cancer, penile cancer, throat mass, genital condyloma, etc.; women are mostly cervical cancer, vulvar cancer, vaginal cancer, anal cancer, head and neck cancer and the like; in addition, the infection of the male reproductive system is also affected, the male genital candidiasis is often caused by the infection of partners or sexual partners or indirect infection, and the candida infection is further aggravated by overlong prepuce or phimosis and local dampness of part of patients. The effects of HPV on the male reproductive system are mainly condyloma acuminata and genital herpes. Also effects on the female reproductive system as some HPV viral types are classified as "high risk" viruses because they cause cellular variation and can lead to reproductive organ cancer: cervical cancer and vaginal cancer are both possibly caused by HPV. In fact, more than 99% of all cervical cancers are caused by these high risk HPV viruses.
At present, the medicines for treating HPV virus are in the form of ointment, suppository for gynecology and external medicines of effervescent preparations, and also have the medicines for treating HPV virus by using vaccine, but the research and development time is long and the risk is high. In the prior art, most of the therapeutic drugs for treating HPV virus have slow effect, long cure course and high cost.
Chinese patent publication No. CN1456194A discloses an anti-hpv ointment, which contains arsenic (a raw material for preparing arsenic trioxide with high risk of use, which is described as octanoic acid, which has high toxicity and enters lung meridian), red lead (containing lead element, which is easily poisoned by lead), and other toxic substances, and thus has high side effects and is easily poisoned by lead. There are also therapeutic drugs for HPV virus using vaccines, but they are long in development time and high in risk. Aiming at the defects in the prior art, the hpv virus resisting medicine has small side effect and good curative effect and is not easy to cause poisoning. Therefore, there is a need to provide a novel complex against HPV viral infection to solve the above-mentioned drawbacks of the prior art.
Therefore, there is a need to provide a new anti-HPV recombinant human gel and a method for preparing the same to solve the above technical problems.
Disclosure of Invention
In order to solve the technical problems, the invention provides an anti-HPV recombinant human gel which has small side effect and good curative effect and is not easy to cause poisoning and a preparation method thereof.
The anti-HPV recombinant human gel provided by the invention comprises: the raw materials comprise the following components in percentage by weight: 1 to 20 percent of compound yolk immunoglobulin, 0.1 to 5 percent of bacteriostatic agent, 0.5 to 10 percent of lubricant, 0.1 to 10 percent of thickening agent and the balance of purified water.
Preferably, the raw materials comprise the following components in percentage by weight: 2 to 15 percent of compound yolk immunoglobulin, 0.2 to 3 percent of bacteriostatic agent, 1 to 5 percent of lubricant, 0.1 to 0.5 percent of thickening agent and the balance of purified water.
Preferably, the raw materials of the compound yolk immunoglobulin comprise the following components: recombinant human collagen, special yolk antibody and yeast beta glucan.
Preferably, the bacteriostatic agent is one or more of polyhexamethylene guanidine, chitosan quaternary ammonium salt and phenoxyethanol.
Preferably, the lubricant is glycerol.
Preferably, the thickener is carbomer.
The preparation method of the anti-HPV recombinant human gel comprises the following steps:
a. adding purified water with the temperature of 40-60 ℃ into stirring equipment, adding Carmholtz into the stirring equipment to dissolve the Carmholtz, stirring for 2.5-4.5h under a heat preservation state, controlling the rotating speed of a stirring blade at 600-800min/r, and preparing gel for later use after stirring;
b. simultaneously adding a bacteriostatic agent, a lubricant and purified water into another stirring device, starting the stirring device, stirring for 1-2h, and controlling the rotating speed of a stirring blade at 500-;
c. after stirring, adding the compound egg yolk immunoglobulin into the stirring equipment with the bacteriostatic agent again, starting the stirring equipment, stirring for 1-2h, and controlling the rotating speed of the stirring blades at 600-;
d. simultaneously adding the gel and the mixed solution prepared in the step into new stirring equipment, starting the stirring equipment at normal temperature, stirring for 2-3h, and controlling the rotating speed of a stirring blade at 800-1000min/r to prepare the anti-HPV recombinant human gel and the preparation method thereof;
e. the prepared anti-HPV recombinant human gel and the preparation method thereof are filled by filling equipment, and the filling container is sterilized.
Preferably, the sterilization mode in the step (e) is ultraviolet sterilization.
Compared with the related technology, the anti-HPV recombinant human gel and the preparation method thereof provided by the invention have the following beneficial effects:
1. the special-shaped yolk antibody is added into the gel, so that the gel has high HPV (human papillomavirus) resistance activity and can well treat HPV; the recombinant human collagen accelerates the rapid repair and regeneration of the erosion tissue and promotes healing; the yeast beta glucan has stronger biological activity of enhancing immunity and repairing cells; the addition of carbomer can adsorb and wrap the inactivated HPV and discharge the HPV out of a body; the addition of the glycerol can adjust the product properties, so that the gel is positioned at the focus position, the acting time is long, and the curative effect is good;
2. the invention uses the compound yolk immunoglobulin as the active component for resisting HPV for the first time, simultaneously gives consideration to other effective components, exerts the multi-component synergistic effect and obtains the product with good quality effect;
3. the product of the invention adopts biological preparation raw materials, and belongs to pure natural antibiotic-free products. Most of the medicaments adopted in the current commonly used medicaments for treating gynecological diseases are antibiotic medicaments, and the medicaments are not only harmful to the organism after being used for a long time, but also can generate drug resistance;
4. the bacteriostatic agent used in the invention is guanidine bacteriostatic agent, is commonly used in vaginal lotion, and has the advantages of no irritation, good bacteriostatic effect and the like. The long-acting bacteriostasis effect is achieved by the combined synergistic effect of a plurality of bacteriostats.
Detailed Description
The present invention will be further described with reference to the following embodiments.
Example 1
anti-HPV recombinant human gels include: the raw materials comprise the following components in percentage by weight: 2 percent of compound yolk immunoglobulin, 0.2 percent of bacteriostatic agent, 1 percent of lubricant, 0.1 percent of thickening agent and the balance of purified water.
The raw materials of the compound yolk immunoglobulin comprise the following components: recombinant human collagen, special yolk antibody and yeast beta glucan.
The bacteriostatic agent is a mixture of polyhexamethylene guanidine, chitosan quaternary ammonium salt and phenoxyethanol.
The lubricant is glycerol.
The thickening agent is carbomer.
The anti-HPV recombinant human gel comprises the following components in percentage by weight: 0.5% of special-shaped yolk antibody, 0.5% of recombinant human collagen, 1% of yeast beta glucan, 0.1% of chitosan quaternary ammonium salt, 0.05% of polyhexamethylene guanidine, 0.05% of phenoxyethanol, 0.1% of carbomer, 1% of glycerol and the balance of purified water.
The preparation method of the anti-HPV recombinant human gel comprises the following steps:
a. adding purified water of 40-60 ℃ into stirring equipment, adding Carmholtz into the stirring equipment to dissolve the Carmholtz, stirring for 2.5 hours under a heat preservation state, controlling the rotating speed of a stirring blade at 600min/r, and preparing gel for later use after stirring;
b. simultaneously adding a bacteriostatic agent, a lubricant and purified water into another stirring device, starting the stirring device, stirring for 1, and controlling the rotating speed of a stirring blade to be 500 min/r;
c. after stirring, adding the compound egg yolk immunoglobulin into the stirring equipment with the bacteriostatic agent again, starting the stirring equipment, stirring for 1h, and controlling the rotating speed of the stirring blades at 600min/r to prepare a mixed solution;
d. simultaneously adding the gel and the mixed solution prepared in the step into a new stirring device, starting the stirring device at normal temperature, stirring for 2h, and controlling the rotating speed of a stirring blade at 800min/r to prepare the anti-HPV recombinant human gel and the preparation method thereof;
e. the prepared anti-HPV recombinant human gel and the preparation method thereof are filled by filling equipment, and the filling container is sterilized.
The sterilization mode in the step (e) is ultraviolet sterilization.
Example 2
anti-HPV recombinant human gels include: the raw materials comprise the following components in percentage by weight: 10% of compound yolk immunoglobulin, 1.2% of bacteriostatic agent, 3% of lubricant, 0.3% of thickening agent and the balance of purified water.
The raw materials of the compound yolk immunoglobulin comprise the following components: recombinant human collagen, special yolk antibody and yeast beta glucan.
The bacteriostatic agent is a mixture of polyhexamethylene guanidine, chitosan quaternary ammonium salt and phenoxyethanol.
The lubricant is glycerol.
The thickening agent is carbomer.
The anti-HPV recombinant human gel comprises 1% of special-shaped yolk antibody, 2% of recombinant human collagen, 7% of yeast beta glucan, 1% of chitosan quaternary ammonium salt, 0.1% of polyhexamethylene guanidine, 0.1% of phenoxyethanol, 0.3% of carbomer, 3% of glycerol and the balance of purified water.
The preparation method of the anti-HPV recombinant human gel comprises the following steps:
a. adding purified water of 40-60 ℃ into stirring equipment, adding Carmholtz into the stirring equipment to dissolve the Carmholtz, stirring for 3.5 hours under a heat preservation state, controlling the rotating speed of a stirring blade at 700min/r, and preparing gel for later use after stirring;
b. simultaneously adding a bacteriostatic agent, a lubricant and purified water into another stirring device, starting the stirring device, stirring for 1.5h, and controlling the rotating speed of a stirring blade at 550 min/r;
c. after stirring, adding the compound egg yolk immunoglobulin into the stirring equipment with the bacteriostatic agent again, starting the stirring equipment, stirring for 1.5h, and controlling the rotating speed of the stirring blades at 700min/r to prepare a mixed solution;
d. simultaneously adding the gel and the mixed solution prepared in the step into a new stirring device, starting the stirring device at normal temperature, stirring for 2.5h, and controlling the rotating speed of a stirring blade at 900min/r to prepare the anti-HPV recombinant human gel and the preparation method thereof;
e. the prepared anti-HPV recombinant human gel and the preparation method thereof are filled by filling equipment, and the filling container is sterilized.
Preferably, the sterilization mode in the step (e) is ultraviolet sterilization.
Example 3
anti-HPV recombinant human gels include: the raw materials comprise the following components in percentage by weight: 15% of compound yolk immunoglobulin, 3% of bacteriostatic agent, 5% of lubricant, 0.5% of thickening agent and the balance of purified water;
the raw materials of the compound yolk immunoglobulin comprise the following components: recombinant human collagen, special yolk antibody and yeast beta glucan.
The bacteriostatic agent is a mixture of polyhexamethylene guanidine, chitosan quaternary ammonium salt and phenoxyethanol.
The lubricant is glycerol.
The thickening agent is carbomer.
The anti-HPV recombinant human gel comprises 3% of a special-shaped yolk antibody, 2% of recombinant human collagen, 10% of yeast beta glucan, 2% of chitosan quaternary ammonium salt, 0.5% of polyhexamethylene guanidine, 0.5% of phenoxyethanol, 0.5% of carbomer, 5% of glycerol and the balance of purified water.
The preparation method of the anti-HPV recombinant human gel comprises the following steps:
a. adding purified water of 40-60 ℃ into stirring equipment, adding Carmholtz into the stirring equipment to dissolve the Carmholtz, stirring for 4.5 hours under a heat preservation state, controlling the rotating speed of a stirring blade at 800min/r, and preparing gel for later use after stirring;
b. simultaneously adding a bacteriostatic agent, a lubricant and purified water into another stirring device, starting the stirring device, stirring for 2 hours, and controlling the rotating speed of a stirring blade at 600 min/r;
c. after stirring, adding the compound egg yolk immunoglobulin into the stirring equipment with the bacteriostatic agent again, starting the stirring equipment, stirring for 2h, and controlling the rotating speed of the stirring blades at 800min/r to prepare a mixed solution;
d. simultaneously adding the gel and the mixed solution prepared in the step into a new stirring device, starting the stirring device at normal temperature, stirring for 3h, and controlling the rotating speed of a stirring blade at 1000min/r to prepare the anti-HPV recombinant human gel and the preparation method thereof;
e. the prepared anti-HPV recombinant human gel and the preparation method thereof are filled by filling equipment, and the filling container is sterilized.
Preferably, the sterilization mode in the step (e) is ultraviolet sterilization.
Comparative example
anti-HPV recombinant human gels include: the raw materials comprise the following components in percentage by weight: 1% of compound yolk immunoglobulin, 1.2% of bacteriostatic agent, 3% of lubricant, 0.3% of thickening agent and the balance of purified water.
The raw materials of the compound type yolk immunoglobulin comprise the following components of special type yolk antibody.
The bacteriostatic agent is a mixture of polyhexamethylene guanidine, chitosan quaternary ammonium salt and phenoxyethanol.
The lubricant is glycerol.
The thickening agent is carbomer.
The anti-HPV recombinant human gel comprises 1% of special-shaped yolk antibody, 1% of chitosan quaternary ammonium salt, 0.1% of polyhexamethylene guanidine, 0.1% of phenoxyethanol, 0.3% of carbomer, 3% of glycerol and the balance of purified water.
The preparation method of the anti-HPV recombinant human gel comprises the following steps:
a. adding purified water of 40-60 ℃ into stirring equipment, adding Carmholtz into the stirring equipment to dissolve the Carmholtz, stirring for 3.5 hours under a heat preservation state, controlling the rotating speed of a stirring blade at 700min/r, and preparing gel for later use after stirring;
b. simultaneously adding a bacteriostatic agent, a lubricant and purified water into another stirring device, starting the stirring device, stirring for 1.5h, and controlling the rotating speed of a stirring blade at 550 min/r;
c. after stirring, adding the compound egg yolk immunoglobulin into the stirring equipment with the bacteriostatic agent again, starting the stirring equipment, stirring for 1.5h, and controlling the rotating speed of the stirring blades at 700min/r to prepare a mixed solution;
d. simultaneously adding the gel and the mixed solution prepared in the step into a new stirring device, starting the stirring device at normal temperature, stirring for 2.5h, and controlling the rotating speed of a stirring blade at 900min/r to prepare the anti-HPV recombinant human gel and the preparation method thereof;
e. the prepared anti-HPV recombinant human gel and the preparation method thereof are filled by filling equipment, and the filling container is sterilized.
Preferably, the sterilization mode in the step (e) is ultraviolet sterilization.
The sample prepared by the embodiment of the invention has the following using effects: volunteers were divided on average into 3 groups of 120 persons each.
Observing volunteers in the group, cleaning the vagina with warm boiled water every night, and coating 3g of the gel prepared in example 2 around labia and inside the vagina;
the control group uses commercial common HPV medicament as control, and the dosage is 3g each time; each group was administered for 4 weeks and then first and second rechecks 12 weeks later;
the contrast group takes the medicament prepared in the comparative example as a contrast, and the dosage is 3g each time; each group was given 4 weeks after the first follow-up and 12 weeks after the second follow-up.
The results are shown in Table 1.
TABLE 1 comparison of clinical efficacy of two groups of patients
As can be seen from the table above, the gel prepared by the invention has the advantages of high cure rate and good curative effect; the comparative example shows that the effective rate is obviously reduced without using the recombinant human collagen and the yeast beta glucan of the invention.
In conclusion, the special-shaped yolk antibody is added into the gel, so that the gel has high anti-HPV activity, can well treat HPV, and can accelerate the rapid repair and regeneration of erosive tissues and promote healing by recombining human collagen; the yeast beta glucan has stronger biological activity of enhancing immunity and repairing cells; the addition of carbomer can adsorb and wrap the inactivated HPV and discharge the HPV out of a body; the addition of glycerol can regulate product properties, so that the gel is positioned at the focus position for a long time and has good curative effect. The composite yolk immunoglobulin is used as an anti-HPV active component for the first time, other effective components are considered at the same time, the multi-component synergistic effect is exerted, and the obtained product has good quality effect. The product adopts biological preparation raw materials, and belongs to pure natural antibiotic-free products. Most of the medicines adopted in the current commonly used medicines for treating gynecological diseases are antibiotic medicines, and the medicines are used for a long time, so that certain damage is caused to the organism, and meanwhile, the organism can generate drug resistance. The bacteriostatic agent is guanidine bacteriostatic agent, is commonly used in vaginal lotion, and has the advantages of no irritation, good bacteriostatic effect and the like. The long-acting bacteriostasis effect is achieved by the combined synergistic effect of a plurality of bacteriostats. Although the existing suppository commonly used in gynecology can be retained in the vagina for a long time, the contact time and the contact area are good, but the suppository easily absorbs water in the vagina to cause dryness, and has certain stimulation and inconvenient use. The invention is a water-like gel, not only has the advantages of the suppository, but also avoids the disadvantages of the suppository, and has better patient compliance.
The above description is only an embodiment of the present invention, and not intended to limit the scope of the present invention, and all modifications of equivalent structures and equivalent processes, which are made by the present specification, or directly or indirectly applied to other related technical fields, are included in the scope of the present invention.
Claims (8)
1. The anti-HPV recombinant human gel is characterized by comprising the following raw materials in percentage by weight: 1 to 20 percent of compound yolk immunoglobulin, 0.1 to 5 percent of bacteriostatic agent, 0.5 to 10 percent of lubricant, 0.1 to 10 percent of thickening agent and the balance of purified water.
2. The anti-HPV recombinant human gel according to claim 1, characterized in that the raw materials thereof comprise the following components and the weight percentages thereof: 2 to 15 percent of compound yolk immunoglobulin, 0.2 to 3 percent of bacteriostatic agent, 1 to 5 percent of lubricant, 0.1 to 0.5 percent of thickening agent and the balance of purified water.
3. The anti-HPV recombinant human gel according to claim 1, wherein the raw materials of the compound type yolk immunoglobulin comprise the following components: recombinant human collagen, special yolk antibody and yeast beta glucan.
4. The anti-HPV recombinant human gel according to claim 1, wherein the bacteriostatic agent is one or more of polyhexamethylene guanidine, chitosan quaternary ammonium salt and phenoxyethanol.
5. The anti-HPV recombinant human gel according to claim 1, wherein said lubricant is glycerol.
6. The anti-HPV recombinant human gel according to claim 1, wherein the thickener is carbomer.
7. The method for preparing anti-HPV recombinant human gel according to any one of claims 1 to 6, characterized in that it comprises the following steps:
a. adding purified water with the temperature of 40-60 ℃ into stirring equipment, adding Carmholtz into the stirring equipment to dissolve the Carmholtz, stirring for 2.5-4.5h under a heat preservation state, controlling the rotating speed of a stirring blade at 600-800min/r, and preparing gel for later use after stirring;
b. simultaneously adding a bacteriostatic agent, a lubricant and purified water into another stirring device, starting the stirring device, stirring for 1-2h, and controlling the rotating speed of a stirring blade at 500-;
c. after stirring, adding the compound egg yolk immunoglobulin into the stirring equipment with the bacteriostatic agent again, starting the stirring equipment, stirring for 1-2h, and controlling the rotating speed of the stirring blades at 600-;
d. simultaneously adding the gel and the mixed solution prepared in the step into new stirring equipment, starting the stirring equipment at normal temperature, stirring for 2-3h, and controlling the rotating speed of a stirring blade at 800-1000min/r to prepare the anti-HPV recombinant human gel and the preparation method thereof;
e. the prepared anti-HPV recombinant human gel and the preparation method thereof are filled by filling equipment, and the filling container is sterilized.
8. The method for preparing anti-HPV recombinant human gel according to claim 7, wherein the sterilization in step (e) is ultraviolet sterilization.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010977040.7A CN112190707A (en) | 2020-09-16 | 2020-09-16 | anti-HPV recombinant human gel and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010977040.7A CN112190707A (en) | 2020-09-16 | 2020-09-16 | anti-HPV recombinant human gel and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112190707A true CN112190707A (en) | 2021-01-08 |
Family
ID=74015220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010977040.7A Pending CN112190707A (en) | 2020-09-16 | 2020-09-16 | anti-HPV recombinant human gel and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112190707A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115154412A (en) * | 2022-07-29 | 2022-10-11 | 湖北特必达生物医疗科技有限公司 | Repairing antibacterial gel and preparation method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104548071A (en) * | 2015-01-27 | 2015-04-29 | 太原锦波生物医药科技有限公司 | Recombinant human-derived collagen vagina gel for vaginal dryness and preparation method thereof |
| CN106177900A (en) * | 2016-08-19 | 2016-12-07 | 吉安市御美丽健康产业股份有限公司 | A kind of gel of anti-human papilloma virus (anti-HPV) and preparation method thereof |
| US20180140659A1 (en) * | 2010-06-29 | 2018-05-24 | Board Of Regents Of The University Of Nebraska | ANALOGS OF C5a AND METHODS OF USING SAME |
| CN108410891A (en) * | 2018-03-07 | 2018-08-17 | 江苏润洁生物科技有限公司 | Therapeutic HPV Yolk antibodies and its application |
| CN109010825A (en) * | 2018-08-27 | 2018-12-18 | 广州汇高生物科技有限公司 | A kind of vagina in-situ gel preparation and its preparation method and application |
| CN110227156A (en) * | 2019-06-12 | 2019-09-13 | 华懿思科(成都)生物科技有限公司 | A kind of elimination gynaecological imflammation pathogenic bacteria and the lgY targeting preparation of HPV viruse and preparation method thereof |
| CN209575501U (en) * | 2018-12-04 | 2019-11-05 | 李强 | The anti-multi-functional dressing of HPV beta glucan |
| CN111632203A (en) * | 2020-06-05 | 2020-09-08 | 中国人民解放军陆军军医大学 | Multifunctional supramolecular hydrogel for preventing postoperative tissue adhesion and preparation method thereof |
-
2020
- 2020-09-16 CN CN202010977040.7A patent/CN112190707A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180140659A1 (en) * | 2010-06-29 | 2018-05-24 | Board Of Regents Of The University Of Nebraska | ANALOGS OF C5a AND METHODS OF USING SAME |
| CN104548071A (en) * | 2015-01-27 | 2015-04-29 | 太原锦波生物医药科技有限公司 | Recombinant human-derived collagen vagina gel for vaginal dryness and preparation method thereof |
| CN106177900A (en) * | 2016-08-19 | 2016-12-07 | 吉安市御美丽健康产业股份有限公司 | A kind of gel of anti-human papilloma virus (anti-HPV) and preparation method thereof |
| CN108410891A (en) * | 2018-03-07 | 2018-08-17 | 江苏润洁生物科技有限公司 | Therapeutic HPV Yolk antibodies and its application |
| CN109010825A (en) * | 2018-08-27 | 2018-12-18 | 广州汇高生物科技有限公司 | A kind of vagina in-situ gel preparation and its preparation method and application |
| CN209575501U (en) * | 2018-12-04 | 2019-11-05 | 李强 | The anti-multi-functional dressing of HPV beta glucan |
| CN110227156A (en) * | 2019-06-12 | 2019-09-13 | 华懿思科(成都)生物科技有限公司 | A kind of elimination gynaecological imflammation pathogenic bacteria and the lgY targeting preparation of HPV viruse and preparation method thereof |
| CN111632203A (en) * | 2020-06-05 | 2020-09-08 | 中国人民解放军陆军军医大学 | Multifunctional supramolecular hydrogel for preventing postoperative tissue adhesion and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| A. DI LONARDO, 等: "Egg yolk antibodies against the E7 oncogenic protein of human papillomavirus type 16", ARCH VIROL, no. 146, pages 117 - 125 * |
| 吴成;: "抗HPV复合免疫球蛋白护理包的临床疗效观察", 临床医药文献电子杂志, no. 31, pages 45 * |
| 陈秀华，等: "抗HPV多克隆卵黄复合免疫球蛋白治疗高危型HPV阳性的临床观察", 兵团医学, vol. 18, no. 4, pages 9 - 10 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115154412A (en) * | 2022-07-29 | 2022-10-11 | 湖北特必达生物医疗科技有限公司 | Repairing antibacterial gel and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003039444A2 (en) | Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases | |
| CN111840516A (en) | Antibacterial gel for gynecology and preparation method thereof | |
| CN110743003A (en) | anti-HPV type vaginal temperature-sensitive gel, preparation method and application thereof | |
| CN112190707A (en) | anti-HPV recombinant human gel and preparation method thereof | |
| WO2022022475A1 (en) | Use of polypeptide in preparation of wound treatment drug | |
| CN112022902A (en) | Preparation method and application of carbon-point modified fluconazole eucalyptus oil microemulsion gel | |
| CN111617115A (en) | Combined medicine for preventing and treating mucosal virus infection and preparation method thereof | |
| CN106177900B (en) | A kind of gel of anti-human papilloma virus (anti-HPV) and preparation method thereof | |
| CN105853463B (en) | A kind of preparation method and application for the Chinese medicine preparation treated ulcerative carbuncle ulcer, promote muscle growth | |
| CN106237029B (en) | A kind of aloe antibiotic gel and preparation method thereof | |
| CN114404565B (en) | Application of beta-Momordica charantia extract in preparation of anti-human papilloma virus infection drugs | |
| CN112546202A (en) | Complexing agent with HPV virus inhibiting function and preparation method thereof | |
| Syed et al. | Human leukocyte interferon-α in cream, for the treatment of genital warts in asian women a placebo-controlled, double-blind study | |
| CN103191163B (en) | Skin wound repairing pharmaceutical composition | |
| CN113244268A (en) | Bacteriostatic gel containing sulfated polysaccharide-nano silver complex and application thereof | |
| CN112316108A (en) | Compositions and methods for promoting and treating chronic wound healing | |
| WO2021051685A1 (en) | Compound formulation for removing hpv | |
| RU2751034C1 (en) | Method of production of a preparation for treatment of bovine endometritis | |
| RU2302881C2 (en) | Antiviral gel as gel based on human leukocyte interferon | |
| KR102644156B1 (en) | Agents to treat skin wounds or burns | |
| RU2744919C1 (en) | Remedy for the treatment of endometritis in cows | |
| WO2012000070A1 (en) | Pharmaceutical composition using stryphnodendron extracts for treating hpv infections | |
| RU2438652C1 (en) | Drug for human papilloma virus associated diseases of uterine neck, presented in form of solution for vaginal irrigations, kit and method for preparing | |
| CN105854071A (en) | Vaginal packing hemostatic material and preparation method thereof | |
| CN105168632A (en) | Traditional Chinese medicinal plastics for promoting healing of wound of cesarean section and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |